Trial Profile
A Multicenter Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the Combination of Rogaratinib and Copanlisib in Patients With FGFR-positive, Locally Advanced or Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Jul 2022
Price :
$35
*
At a glance
- Drugs Copanlisib (Primary) ; Rogaratinib (Primary)
- Indications Carcinoma; Solid tumours; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ROCOCO
- Sponsors Bayer
- 18 Mar 2021 Status changed from active, no longer recruiting to completed.
- 12 Jan 2021 Planned End Date changed from 30 Nov 2020 to 29 Jan 2021.
- 04 Nov 2020 Planned End Date changed from 30 Sep 2020 to 30 Nov 2020.